Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data

An 18-month analysis of follow-up data showed that Moderna's RSV vaccine was just about 49.9% effective in preventing RSV-LRTD. This is significantly lower compared with the 80.9% vaccine efficacy achieved by the vaccine at a follow-up period of 3.7 months. Image Source: Zacks Investment Research This efficacy rate was also significantly lower compared with GSK's Arexvy and Pfizer's Abrysvo, both of which are also approved for similar use by the FDA. These companies also presented data on their respective R ...